Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 16/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359756 | 1.00 | ADORA3 (0.52) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL5372681 | 0.87 | ADORA3 (0.48) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5369682 | 0.87 | ADORA3 (0.48) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL14518675 | 0.84 | ADORA3 (0.48) | ADORA3ADORA1ADORA2AYTHDC1 | |
| SCHEMBL14518674 | 0.84 | ADORA3 (0.56) | ADORA3ADORA1ADORA2A | |
| SCHEMBL5365273 | 0.84 | ADORA3 (0.66) | ADORA3ADORA1ADORA2A | |
| SCHEMBL14518677 | 0.84 | ADORA3 (0.66) | ADORA3ADORA1ADORA2A | |
| SCHEMBL5364016 | 0.83 | ADORA3 (0.61) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5365914 | 0.83 | ADORA3 (0.61) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6395427 | 0.80 | ADORA3 (0.69) | ADORA3ADORA1ADORA2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199127-B2 | Purine nucleosides | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199127-B2 | Purine nucleosides | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050256143-A1 | Purin-9-yl-tetrahydrothiophene-3,4-diols; anticarcinogenic agents selective to A3 adenosine receptors; breast cancer | Government of the United States of America, repres ented by The Secretary, Department of Health and (US) | 2005-11-17 | — | — | US | disclosed |
| EP-1578758-A2 | PURINE NUCLEOSIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004038006-A2 | PURINE NUCLEOSIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256143-A1 | Purin-9-yl-tetrahydrothiophene-3,4-diols; anticarcinogenic agents selective to A3 adenosine receptors; breast cancer | ADORA3, P2RX3, P2RY1 | ADORA3 1/4885ADORA1 5/4885ADORA2A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.